Bedsore Medicine Market

Key data points: Market size in 2027 = $1.9 billion and 2035 = $2.1 billion, growth forecast = 2.9% annually for the next 8 years. Scroll below to get more insights. This market report covers trends, opportunities and forecasts in bedsore medicine market to 2035 by type (dressing and antibiotic ointment), application (hospital, clinic, pharmacy, and online), and region (North America, Europe, Asia Pacific, and the Rest of the World) Bedsore Medicine Market The future of the global bedsore medicine market looks promising with opportunities in the hospital, clinic, pharmacy, and online markets. The global bedsore medicine market is expected to reach an estimated $2.1 billion by 2035 from $1.9 billion in 2027 with a CAGR of 2.9% from 2027 to 2035. The major drivers for this market are the increasing incidence of pressure ulcer cases, the rising geriatric population requiring wound care, and the growing adoption of advanced wound dressings. • Lucintel forecasts that, within the type category, dressing is expected to witness higher growth over the forecast period due to dressing ease of use and protection against leakage of wound fluid. • Within the application category, online is expected to witness the highest growth over the forecast period due to increased ease and convenience of online pharmacy. • In terms of regions, APAC is expected to witness the highest growth over the forecast period due to growth of e-Commerce and changes in the accessibility of Healthcare services. Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below. Emerging Trends in Bedsore Medicine Market Bedsore medicine market is expected to advance toward prevention and infection control with tissue healing and regeneration during the forecast period (2025-2027). Discharge of elderly patients and pressure injury prevention targets has increased focus on home based wound care. Limited reimbursement and increasing scrutiny on out-lier payments by third party administrators has affected buying patterns. Our report suggests that demand is for products which are clinically effective and ease the burden of administration and reduce total cost of treatment. • Sustainability: Continued efforts to decrease the use of chlorinated solvents and non-recyclable components in advanced wound care products will continue. Increased emphasis on footprint reductions in advanced wound care products by buyers in the Healthcare sector will be aimed at reducing the ecological footprint. • Advanced Wound Care Products: The use of products with moisture balance, and extended wear time will continue to gain in popularity. The next update of pressure ulcer prevention and treatment guidelines in Europe is expected in the next 3-5 years and may influence product preferences. • Digital Wound Care: The adoption of digital and electronic records for documenting and measuring wounds in home and hospital based care will continue to increase in the next 5 to 10 years. The increasing prevalence of diabetes will create an increased demand for digital and remote wound care monitoring. • Home-based Care: Treatment provided outside of a clinical setting (i.e. telehealth, home visits, mobile Care teams, etc.) is growing, especially among the elderly. In 2030, the WHO estimates there will be 1.4 billion people aged 60 and above. Convenient product design and simple-to-follow product use protocols will lead product development and increase market penetration. • Regenerative Medicine: Alternative therapies to traditional wound care and tissue-repair products continue to emerge. Negative pressure Wound Therapy (NPWT) is gaining traction as are delivery systems for therapeutic growth factors. Some biologic products have recently received FDA approval for the management of chronic and hard-to-heal wounds. Additional biologic products may gain traction in the marketplace in the next five years, especially if they are proven to be effective and reimbursed by payers. There are clear trends in the marketplace toward products that help prevent chronic conditions and promote care outside of the hospital. Product differentiation along these lines will help recover and defend adequate market share. Commoditization will be the market fate for products that lack integrated healing outcomes. The public market will continue to dictate pricing constraints. Long-term partnerships between manufacturers and integrators (i.e., clinicians, distributors) will help durable products and platforms thrive. Recent Developments in the Bedsore Medicine Market Product development of bedsore medication is expected to focus on biologics and smart products integrated in advanced wound care and trauma management. Expect a strong influence of reimbursement policies on adoption, especially for the elderly, in long term care and in the community. • Biologics for Pressure Injuries and Wounds: A number of suppliers are developing advanced tissue-engineered products for pressure injuries and wounds and related products. The 2025 CMS rules are expected to standardize payments for certain skin and tissue substitutes, thus fostering price competition for suppliers to demonstrate clinical and economic outcomes. • Advanced Wound Care: Suppliers are launching advanced, technology-enabled products for wound care. Leading suppliers are investing in product innovation, e.g. Smith & Nephew reported 2024 wound care and leg, foot and other orthopedic supports and braces product revenue of $6 billion. Suppliers will differentiate advanced, technology-enabled products based on total cost and other value-based outcomes. • Partnerships for Prevention and Clinical Data: Suppliers are integrating advanced pressure-relieving surfaces and other products with EHRs to capture clinical data. The 2025 NHS IP allows trusts to prioritize prevention of pressure injuries, and other injuries. Thus, there is increased focus on advanced products that integrates clinical data and software to automate best practice prevention and health promotion. • Wound Supplier Expansion: The U.S. Census expects the over 65 population to reach 71.5 million by 2025. As this happens, the withdrawal of care from the community to the hospital will continue. The shifting demographics will increase the need for outlying care, which will be delivered using less (or no) face-to-face interaction. Further, the care may be provided by a non-healthcare professional. • Purchasing Shifts: The focus of the U.S. healthcare system is gradually changing to value-based payment. In hospitals, shifts are occurring in how the purchase of devices is managed. The focus of the shifts is on the length of time a given device will take to pay for itself and on the infectious nature of the device and how long it takes for a given wound to heal. The FDA is expected to review a number of wound-management technologies by 2025. The goal of wound-healing biotechnology is the repair and remodeling of tissues. The best commercial opportunities are in the preventative care of wound complications, and digitally-assisted care. Depending on the nature of the wound, the care may be provided in the community or in the hospital. The better the evidence, and the more places the technology is available for sale, the better the opportunities to recover the cost of the product. Strategic Growth Opportunities in the Bedsore Medicine Market Bedsore medicine is moving beyond simple topical treatments and focus is shifting toward prevention and healing. Population aging, reimbursement policies of hospitals, proper home health care, and improved diagnosis will increase the market from 2024 to 2026. According to Lucintel, there are ample opportunities in this field where substantial clinical evidence, reimbursement policies, and ease of use of a product merge. • Use of Advanced Biologics: In the field of wound care, advancement has been primarily in the use of different growth factors, cellular matrix and other combination therapies. As of March, 2025, the FDA had wound product codes for 20 or more cellular and tissue based products. Clinical evidence and usability of a product will be the primary factor for pricing and reimbursement in the field of wound care in the next 5 years. • Pressure Injury Prevention and Treatment: There has been significant improvement in the materials used for wound care and treatment. Negative pressure wound therapy and other telehealth and remote monitoring systems will allow treatment and prevention of pressure injuries to be shifted from hospitals to the home. Payments made to hospitals by CMS under the Hospital Acquired Condition Reduction Program will help fund research to develop new products. • Digital Wound Monitoring: Imaging software and connected mattresses, in conjunction with risk-assessment tools, have the potential to create new sources of revenue from drugs. In April 2025, the FDA’s database indicated that over 700 wound-care-related medical devices had been cleared. Objective software to monitor healing may promote the proactive management of wounds, improve the code director’s assessment of wound healing, and facilitate the adoption of more appropriate and valuable wound healing interventions. • Long-term Care: The use of lower-complexity products, in conjunction with standardized processes, in nursing homes and rehabilitation centers has the potential to be profitable. In February 2025, the CMS reported that over 1.2 million people resided in Medicare-participating nursing homes. Companies that develop products or solutions to address the staffing challenges in these facilities are likely to be successful and may gain lasting business in the short-term. • Biomaterials: The use of polymeric systems, packaging systems, and wound dressings that integrate principles of design for sustainability may improve the competitiveness of wound care products. The EU’s Packaging and Packaging Waste Directive will likely come into effect for Member States in August 2026. The authorization of these directives may improve the position of certain suppliers to gain access to the procurement of healthcare services. The largest opportunities will come from products that decrease the time spent by the caregiver to accomplish other tasks while demonstrating clinical evidence of wound healing. Early integration of reimbursement and clinical teams will facilitate the creation of products that achieve the greatest clinical impact. The international business will be pursued; however, the quality of the company’s distribution channels and education of the local healthcare professionals will influence the company’s success Bedsore Medicine Market Drivers and Challenges Retain the content's layout (i.e. bullet points, spacing, Headings, etc.) as closely as possible. Do not alter the companies cited in the content. Lucintel and other similar names must be correctly spelled. These sentences will not be included in the final copy. Growing and aging populations create more demand for bedsore treatment medications. Lucintel mentions that the focus on patient care and the encouragement of innovation will stimulate the bedsore treatment medication market. The factors responsible for driving this market include : • Aging Population: It is predicted that by the year 2030, the global population aged 60 years and above will be 1.4 billion. The increase in elderly people will increase the at risk population for pressure ulcers and other injuries. Long term policies of various nations will ensure continuous increase in the demand for products and services to prevent pressure sores. • Technology: Antimicrobial agents and advanced biomaterials have improved the management of wounds. Similar developments are occurring in the areas of smart dressings, digital monitoring and oxygen therapy. Sensor-based technologies that alert to the presence of decubitus ulcers and other wounds are becoming available and may stimulate the development of new treatments. The use of data to drive decisions in medicine will promote the use of advanced treatments for pressure ulcers in both hospitals and home care. • Growth in Health Care Spending: Increased spending on health care will allow facilities to purchase more advanced wound care products and technologies. It is expected that health care spending will increase due to the rise of chronic health conditions. In the medium-term, the improved ability and will of health care systems in the poorer nations to fund wound care services will drive the growth of the market. • Improved Standards: Various initiatives of national and international health care agencies to improve the quality of care and reduce health care associated conditions fostered improvements in prevention and treatment of pressure ulcers. Standardization of methods and procedures has allowed for a better clinical framework. In the 2025-2029 time frame, it is expected that greater demands for quality in health care will create a greater demand for improved bedsore management technologies. • Product Innovation: New antimicrobial gels and ointments, collagen-based products, and hydrocolloid dressings are examples of products targeting the first stages of wound healing. Negative pressure wound therapy and combination products focus on the later stages. Innovation helps clinicians manage individual cases and minimize complications. In the short term, the bedsore medicine market will benefit from the increased competition from products derived from recent advances in technology. The challenges facing this market include: • High Treatment Costs: The use of sophisticated products and extended duration of care increases financial burden on the healthcare system and delays wound healing. In May 2025, health personnel mentioned financial and staffing resources constraints. During the next three to five years, the high degree of income and product price dependency will result in restricted access in low and middle income countries. Inadequate and slow reimbursement policies will further limit the use of bedsore medicine in developing countries. • Complex Clinical Management: The presence of complications, such as pressure sores, usually leads to the use of other products and services (e.g., dietary and physical therapy, infection control products, and aids to assist ambulation). In July 2025, the use of integrated and multidisciplinary medicine and teams was also cited. Noncompliance with clinical guidelines and poor adherence to treatment increases the duration of the healing process and the risk of complication. The variation in the clinical condition and the degree of adherence to treatment in the general population will result in unstable and unpredictable demand for bedsore medicine. • Access Gaps: Non-uniform insurance, rural healthcare, and varying drug approvals can restrict patients’ access to innovative therapies. As of September 2025, the majority of healthcare systems hadn’t changed their policies for funding innovative therapies; however, many limited reimbursement for advanced wound care. These access gaps can hinders the market growth and investment for innovative therapies. In the next 3 to 5 years, various therapies will be developed with better reimbursement potential and more convenient means of distribution. Changes within the bedsore treatment market will be influenced by long-term trends including increased public and private investment in healthcare, economic growth, advances in medical technology, and greater regulation of the medical industry. Together, these will likely improve diagnosis, treatment, and monitoring of patients. The cost and complexity of treatment may continue to limit the adoption of medical innovations. The most successful companies will be able to integrate multiple elements of a given market including affordability, performance, and distribution. The most successful companies will also integrate collaborations with various industry stakeholders to enhance integration of innovative medical devices. List of Bedsore Medicine Market Companies Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies bedsore medicine market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the bedsore medicine market companies profiled in this report include- • Nipro • Chongqing Kerui Pharmaceutical • Smith & Nephew • Convatec • B Braun Melsungen Bedsore Medicine Market by Segment The study includes a forecast for the global bedsore medicine market by type, application, and region. Bedsore Medicine Market by Type [Value ($B) from 2019 to 2035]: • Dressing • Antibiotic Ointment Bedsore Medicine Market by Application [Value ($B) from 2019 to 2035]: • Hospital • Clinic • Pharmacy • Online Bedsore Medicine Market by Region [Value ($B) from 2019 to 2035]: • North America • Europe • Asia Pacific • The Rest of the World Country Wise Outlook for the Bedsore Medicine Market Advanced wound dressings combined with digital and other forms of monitoring are expected to play an increasing role in the prevention and management of pressure injuries. From 2025 to 2027 the implementation of new reimbursement policies and the hospital Acute Care Act, together with new investments in the production of medical devices, will influence procurement. The Lucintel report published in 2022 indicated the above mentioned policies and programs would enhance the market’s interest in evidence based products. • USA: The Centers for Medicare and Medicaid Services (CMS) have included the prevention of pressure ulcers in their Hospital Acquired Condition reduction program, which means participating hospitals would face a 1% reduction in their reimbursement for the program period (from October 2025 to September 2028). This would encourage the purchase of pressure ulcer prevention products and services by hospitals for the program period. • China: In 2025 the Chinese medical device regulatory agency (NMRA) continued its program of prioritized reviews for innovative medical devices. At the same time several Chinese companies expanded their portfolio of advanced wound-healing products. As a result, several suppliers of wound care products reported a double-digit growth in their China sales (December 2025). • Germany: German manufacturers of wound care products have further adapted their offerings in the German market in response to the requirements of the EU MDR. Transition periods for Class III medical devices end on December 31, 2027. The European Commission recently approved a request from industry to extend these deadlines. Bed sore prevention and treatment products will only be available at German hospitals for which the market has remained open for the bedsore prevention and treatment products. • India: The digital health records initiative Ayushman Bharat has crossed 750 million health records. This initiative has the potential to improve the documentation of chronic wounds and pressures injuries. Improved documentation has the potential to improve integrated and continuous wound care. Increased transparency has the potential to enhance the procurement of wound care products. • Japan: The home care policy of Japan’s Ministry of Health, Labor and Welfare has promoted the development of easy-to-use bedsore products. These products are expected to have a positive impact on the pressure injury prevention outside of acute care facilities. Features of the Global Bedsore Medicine Market Market Size Estimates: bedsore medicine market size estimation in terms of value ($B). Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions. Segmentation Analysis: bedsore medicine market size by type, application, and region in terms of value ($B). Regional Analysis: bedsore medicine market breakdown by North America, Europe, Asia Pacific, and Rest of the World. Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the bedsore medicine market. Strategic Analysis: This includes M&A, new product development, and competitive landscape of the bedsore medicine market. Analysis of competitive intensity of the industry based on Porter’s Five Forces model. If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more. This report answers following 11 key questions: Q.1. What are some of the most promising, high-growth opportunities for the bedsore medicine market by type (dressing and antibiotic ointment), application (hospital, clinic, pharmacy, and online), and region (North America, Europe, Asia Pacific, and the Rest of the World)? Q.2. Which segments will grow at a faster pace and why? Q.3. Which region will grow at a faster pace and why? Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market? Q.5. What are the business risks and competitive threats in this market? Q.6. What are the emerging trends in this market and the reasons behind them? Q.7. What are some of the changing demands of customers in the market? Q.8. What are the new developments in the market? Which companies are leading these developments? Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth? Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution? Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?